C4 Therapeutics, Inc. (CCCC): Cash & Equivalents
$74.60M
As of 2025-12-31
$78.61M
As of 2026-06-30
+35.9%
3-year compound annual growth
-16.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $74.60M | +34.4% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $55.50M | -56.2% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $126.59M | +325.5% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $29.75M | -60.9% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $76.12M | -58.1% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $181.73M | +100.7% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $90.55M | n/a | 2022-02-24, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $74.60M | +34.4% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $217.05M | +289.7% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $110.82M | +29.0% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $357.01M | +196.9% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $20.95M | -50.0% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $65.30M | -8.5% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $146.65M | +11.5% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $4.96M | +51.4% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $36.79M | +38.1% |
Compare CCCC, XFOR, DTIL, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗